Century Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.3
- Today's High:
- $2.4671
- Open Price:
- $2.43
- 52W Low:
- $2.28
- 52W High:
- $11.95
- Prev. Close:
- $2.36
- Volume:
- 48031
Company Statistics
- Market Cap.:
- $147.62 million
- Book Value:
- 4.174
- Revenue TTM:
- $4.56 million
- Operating Margin TTM:
- -2804.16%
- Gross Profit TTM:
- $5.20 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.84%
- Return on Equity TTM:
- -41.94%
Company Profile
Century Therapeutics Inc had its IPO on 2021-06-18 under the ticker symbol IPSC.
The company operates in the Healthcare sector and Biotechnology industry. Century Therapeutics Inc has a staff strength of 163 employees.
Stock update
Shares of Century Therapeutics Inc opened at $2.43 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.3 - $2.47, and closed at $2.33.
This is a -1.27% slip from the previous day's closing price.
A total volume of 48,031 shares were traded at the close of the day’s session.
In the last one week, shares of Century Therapeutics Inc have slipped by -5.67%.
Century Therapeutics Inc's Key Ratios
Century Therapeutics Inc has a market cap of $147.62 million, indicating a price to book ratio of 1.5109 and a price to sales ratio of 102.4926.
In the last 12-months Century Therapeutics Inc’s revenue was $4.56 million with a gross profit of $5.20 million and an EBITDA of $-116228000. The EBITDA ratio measures Century Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Century Therapeutics Inc’s operating margin was -2804.16% while its return on assets stood at -16.84% with a return of equity of -41.94%.
In Q2, Century Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 92.9%.
Century Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Century Therapeutics Inc’s profitability.
Century Therapeutics Inc stock is trading at a EV to sales ratio of 40.6871 and a EV to EBITDA ratio of -1.5907. Its price to sales ratio in the trailing 12-months stood at 102.4926.
Century Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $417.16 million
- Total Liabilities
- $19.16 million
- Operating Cash Flow
- $6.97 million
- Capital Expenditure
- $4.50 million
- Dividend Payout Ratio
- 0%
Century Therapeutics Inc ended 2024 with $417.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $417.16 million while shareholder equity stood at $247.57 million.
Century Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $19.16 million in other current liabilities, 6000.00 in common stock, $-583652000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $64.44 million and cash and short-term investments were $156.40 million. The company’s total short-term debt was $1,183,000 while long-term debt stood at $0.
Century Therapeutics Inc’s total current assets stands at $161.28 million while long-term investments were $144.58 million and short-term investments were $91.96 million. Its net receivables were $1.71 million compared to accounts payable of $3.63 million and inventory worth $-1706000.00.
In 2024, Century Therapeutics Inc's operating cash flow was $6.97 million while its capital expenditure stood at $4.50 million.
Comparatively, Century Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.33
- 52-Week High
- $11.95
- 52-Week Low
- $2.28
- Analyst Target Price
- $18.3
Century Therapeutics Inc stock is currently trading at $2.33 per share. It touched a 52-week high of $11.95 and a 52-week low of $11.95. Analysts tracking the stock have a 12-month average target price of $18.3.
Its 50-day moving average was $2.79 and 200-day moving average was $4.13 The short ratio stood at 12.81 indicating a short percent outstanding of 0%.
Around 3770.2% of the company’s stock are held by insiders while 5321.5% are held by institutions.
Frequently Asked Questions About Century Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.